Literature DB >> 10495407

Hormone replacement therapy affects body composition and leptin differently in obese and non-obese postmenopausal women.

K Kristensen1, S B Pedersen, P Vestergaard, L Mosekilde, B Richelsen.   

Abstract

Leptin and oestrogen are both involved in the regulation of adipose tissue deposition and feeding behaviour. We investigated whether 5 years of hormone replacement therapy (HRT) affected serum leptin and body composition differently in 89 postmenopausal women treated with HRT compared with 178 controls. At baseline, leptin was significantly correlated with oestradiol (r=0.13, P<0.05) and in multiple backward regression analysis including oestradiol and any estimate of body fat, oestradiol remained a significant determinant of leptin levels. In the control group, all estimates of body fat determined by dual energy X-ray absorptiometry (DEXA) or anthropometry were increased (3.6-16.9%) and leptin increased 31.3% (16.03+/-1.02 to 20.84+/-1.2 ng/ml (s.e.m.), P<0.001). In the HRT group all estimates of body composition also increased during the 5-year observation but to a lesser extent than observed in the control group (1.0-8.5%). Leptin was raised by 19.7% (17.81+/-1.32 to 20.57+/-1.65 ng/ml, P<0.001). However, the DEXA scans revealed that the control group gained 2.4-fold more fat during the 5-year observation (1.9+/-0.3 vs 0.8+/-0.4 kg, P<0.05), and especially the trunk fat increased (1.4+/-0.2 vs 0.7+/-0.3 kg, P<0.05). This was reflected in the increase in leptin levels, which were increased by 7.4% in the control group compared with the HRT group (4.81+/-0.60 vs 2.76+/-0.87 ng/ml, P<0.05). Adjusting for the difference in adipose tissue revealed that HRT had no independent effect on leptin levels. Comparisons between obese (body mass index>25 kg/m(2)) and non-obese (<25 kg/m(2)) subjects by stratifying for HRT treatment using multiple linear regression revealed that the change in fat mass was significantly less among treated subjects (P=0.038) and especially in the non-obese subjects (P=0.001). The change in trunk fat was similarly correlated with treatment status (P=0.029) and with the degree of obesity (P=0.006). In conclusion, 5 years of HRT treatment significantly reduced fat mass accumulation, especially in the trunk region. This effect of HRT was more pronounced in non-obese as compared with obese subjects. The HRT-induced reduction in fat mass seems not to be mediated by leptin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10495407     DOI: 10.1677/joe.0.1630055

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  19 in total

1.  Regulation of energy expenditure by estradiol in premenopausal women.

Authors:  Edward L Melanson; Kathleen M Gavin; Karen L Shea; Pamela Wolfe; Margaret E Wierman; Robert S Schwartz; Wendy M Kohrt
Journal:  J Appl Physiol (1985)       Date:  2015-09-03

2.  Acute modulation of adipose tissue lipolysis by intravenous estrogens.

Authors:  Rachael E Van Pelt; Wendolyn S Gozansky; Robert C Hickner; Robert S Schwartz; Wendy M Kohrt
Journal:  Obesity (Silver Spring)       Date:  2006-12       Impact factor: 5.002

Review 3.  Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia.

Authors:  G Onder; C Della Vedova; F Landi
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

4.  Preventive effects of raloxifene treatment on agerelated weight loss in postmenopausal women.

Authors:  Tomohiko Urano; Masataka Shiraki; Tatsuhiko Kuroda; Shiro Tanaka; Kazuhiro Uenishi; Satoshi Inoue
Journal:  J Bone Miner Metab       Date:  2016-01-11       Impact factor: 2.626

5.  Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment.

Authors:  Karen L Shea; Kathleen M Gavin; Edward L Melanson; Ellie Gibbons; Anne Stavros; Pamela Wolfe; John M Kittelson; Sheryl F Vondracek; Robert S Schwartz; Margaret E Wierman; Wendy M Kohrt
Journal:  Menopause       Date:  2015-10       Impact factor: 2.953

6.  Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials.

Authors:  Jennifer W Bea; Qiuhong Zhao; Jane A Cauley; Andrea Z LaCroix; Tamsen Bassford; Cora E Lewis; Rebecca D Jackson; Frances A Tylavsky; Zhao Chen
Journal:  Menopause       Date:  2011-01       Impact factor: 2.953

Review 7.  Postmenopausal hormone therapy: an Endocrine Society scientific statement.

Authors:  Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; Graham A Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian
Journal:  J Clin Endocrinol Metab       Date:  2010-06-21       Impact factor: 5.958

Review 8.  Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors.

Authors:  Jin-Qiang Chen; Terry R Brown; Jose Russo
Journal:  Biochim Biophys Acta       Date:  2009-04-05

Review 9.  Is there evidence that estrogen therapy promotes weight maintenance via effects on leptin?

Authors:  Alyse M Springer; Karen Foster-Schubert; Gregory J Morton; Ellen A Schur
Journal:  Menopause       Date:  2014-04       Impact factor: 2.953

10.  Estradiol regulates daily rhythms underlying diet-induced obesity in female mice.

Authors:  Oluwabukola Omotola; Sandra Legan; Emily Slade; Ayooluwatomiwa Adekunle; Julie S Pendergast
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-11-05       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.